Natale Sheehan, MD
Medical Oncology · Jackson, MSNPI 1518178524
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.4% of the total across 230 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 48 manufacturers, the largest accounting for just 10.7% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,205, 2.6 times the $470 reported in 2019. That places this record below the midpoint for medical oncology clinicians in MS, where the typical reported total is $7,285.
Across 230 payments — averaging $17.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$429
- Bristol Myers Squibb$389
- Gilead$337
- Merck$315
- Pfizer$226
- Deciphera Pharmaceuticals Inc.$225
- plus $2K from 42 others
Across 10 payments — averaging $7807.96 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Mirati Therapeutics, Inc.$68K
- Eli Lilly$10K
What the payments were for
- Food & beverage$3,93498%
- Education$632%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$3,997 in reported general payments places this provider in the 30th percentile of 20 medical oncology providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 78 | $1,186,057 |
| BrukinsaZanubrutinib | 29 | $397,560 |
| ImbruvicaIbrutinib | 25 | $372,371 |
| RevlimidLenalidomide | 26 | $366,824 |
| LynparzaOlaparib | 16 | $260,361 |
| FruzaqlaFruquintinib | 11 | $245,156 |
| VerzenioAbemaciclib | 12 | $177,849 |
| TavalisseFostamatinib Disodium | 12 | $170,537 |
| ZarxioFilgrastim-Sndz | 18 | $38,542 |
| Abiraterone Acetate | 12 | $27,000 |
| EliquisApixaban | 14 | $15,837 |
| Exemestane | 16 | $6,496 |
| Letrozole | 345 | $4,442 |
| Tamoxifen Citrate | 134 | $3,094 |
| Imatinib Mesylate | 15 | $2,343 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Beigene USA, Inc.Brukinsa | $41 | $397,56029 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $115 | $372,37125 claims |
| Bristol Myers SquibbRevlimid | $389 | $366,82426 claims |
| AstraZenecaLynparza | $207 | $260,36116 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Fruzaqla | $12 | $245,15611 claims |
| PfizerEliquis | $226 | $15,83714 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 20 medical oncology providers in Mississippi.
Other medical oncology in Jackson
- James ThigpenJackson$41K
- Tammy YoungJackson$12K
- Elizabeth HerringtonJackson$10K
- Manubhai PatelJackson$7K
- Robert HamiltonJackson$6K
- Nicole ClevelandJackson$6K
- Louis PunekyJackson$5K
- Otis BrunsonJackson$3K
- John RuckdeschelJackson$2K
- Ralph VanceJackson$173
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.